{"id":919614,"date":"2025-12-15T08:34:46","date_gmt":"2025-12-15T13:34:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/"},"modified":"2025-12-15T08:34:46","modified_gmt":"2025-12-15T13:34:46","slug":"okyo-pharma-announces-chairman-and-founder-acquires-shares-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/","title":{"rendered":"OKYO Pharma Announces Chairman and Founder Acquires Shares"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LONDON and NEW YORK, Dec.  15, 2025  (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (NASDAQ:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oTvS4kxNqwlsGLsCrKIBXzAGrxVpadhkuaGdaCFipoRK7yiaMa3le-6uE0yPl4Y2vV4quGWDBQb8sp2C0-ZnsaPhNdbTwQa4XYbKIF6wfaAtH81mss7SPgN8G33a9-e2\" rel=\"nofollow\" target=\"_blank\">OKYO<\/a>), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company\u2019s ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares.<\/p>\n<p align=\"justify\">\n        <strong>About Urcosimod (Formerly called OK-101)<\/strong><br \/>\n        <br \/>Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating ocular diseases. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the efficacy of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and just completed a randomized, placebo-controlled, double-masked Phase 2 trial of urcosimod to treat neuropathic corneal pain.<\/p>\n<p align=\"justify\">\n        <strong>About OKYO<\/strong><br \/>\n        <br \/>OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.<\/p>\n<p>For further information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RXinnNHJxnZypqfkdfV2ZO6Do_VxRd83wmnHA0TNbLp7zgQNgFy6buCN7TZYpS2eMYjfeHaWZy4W1pdxKUfASRMuVhCH1Q0NLuerR0IzSCQ=\" rel=\"nofollow\" target=\"_blank\">www.okyopharma.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <u>Inquiries:<\/u><br \/>\n        <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:33%;width:33%;min-width:33%;vertical-align: top\">\n            <strong>Business Development &amp;<br \/>Investor Relations<\/strong>\n          <\/td>\n<td style=\"max-width:34%;width:34%;min-width:34%;vertical-align: top\">Paul Spencer<\/td>\n<td style=\"max-width:33%;width:33%;min-width:33%;vertical-align: top\">+44 (0)20 7495 2379<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjA2OGI5MTctODI5My00YmZjLWIwNzktNjA4YzM0NTJhNTIyLTEyMTI5OTYtMjAyNS0xMi0xNS1lbg==\/tiny\/OKYO-Pharma-LTD.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (NASDAQ:\u00a0OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company\u2019s ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares. About Urcosimod (Formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OKYO Pharma Announces Chairman and Founder Acquires Shares&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-919614","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OKYO Pharma Announces Chairman and Founder Acquires Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OKYO Pharma Announces Chairman and Founder Acquires Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (NASDAQ:\u00a0OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company\u2019s ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares. About Urcosimod (Formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well &hellip; Continue reading &quot;OKYO Pharma Announces Chairman and Founder Acquires Shares&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T13:34:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OKYO Pharma Announces Chairman and Founder Acquires Shares\",\"datePublished\":\"2025-12-15T13:34:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/\"},\"wordCount\":334,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/\",\"name\":\"OKYO Pharma Announces Chairman and Founder Acquires Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM=\",\"datePublished\":\"2025-12-15T13:34:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OKYO Pharma Announces Chairman and Founder Acquires Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OKYO Pharma Announces Chairman and Founder Acquires Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/","og_locale":"en_US","og_type":"article","og_title":"OKYO Pharma Announces Chairman and Founder Acquires Shares - Market Newsdesk","og_description":"LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (NASDAQ:\u00a0OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company\u2019s ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares. About Urcosimod (Formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well &hellip; Continue reading \"OKYO Pharma Announces Chairman and Founder Acquires Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-15T13:34:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OKYO Pharma Announces Chairman and Founder Acquires Shares","datePublished":"2025-12-15T13:34:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/"},"wordCount":334,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/","name":"OKYO Pharma Announces Chairman and Founder Acquires Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM=","datePublished":"2025-12-15T13:34:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMjA1MiM3MzIxNTYxIzIyMDE0NDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-announces-chairman-and-founder-acquires-shares-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OKYO Pharma Announces Chairman and Founder Acquires Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=919614"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919614\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=919614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=919614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=919614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}